Cost–Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden

INTRODUCTION: This study aimed to assess the costs and benefits of three alternative second-line treatment strategies for Swedish patients with type 2 diabetes mellitus (T2DM) who fail to reach glycated hemoglobin (HbA1c) ≤ 7% with metformin treatment alone: glucagon-like peptide-1 (GLP-1) receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiadaliri, Aliasghar A., Gerdtham, Ulf G., Eliasson, Bjorn, Carlsson, Katarina Steen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269657/
https://www.ncbi.nlm.nih.gov/pubmed/25213800
http://dx.doi.org/10.1007/s13300-014-0080-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269657/
https://www.ncbi.nlm.nih.gov/pubmed/25213800
http://dx.doi.org/10.1007/s13300-014-0080-0

Ejemplares similares